Modality
Degrader
MOA
KIF18Ai
Target
LAG-3
Pathway
PD-1/PD-L1
Endometrial CaMeso
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
~Jun 2021
→ ~Sep 2022
Phase 2
Dec 2022
→ Jul 2027
Phase 2Current
NCT06343050
2,964 pts·Endometrial Ca
2022-12→2026-04·Recruiting
NCT04634100
647 pts·Endometrial Ca
2023-09→2027-07·Completed
3,611 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-274w awayPh2 Data· Endometrial Ca
2027-07-171.3y awayPh2 Data· Endometrial Ca
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2026-04-27 · 4w away
Endometrial Ca
Ph2 Data
2027-07-17 · 1.3y away
Endometrial Ca
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06343050 | Phase 2 | Endometrial Ca | Recruiting | 2964 | ORR |
| NCT04634100 | Phase 2 | Endometrial Ca | Completed | 647 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |